Evaluation of the safety of cefepime prolonged infusions in pediatric patients with cystic fibrosis.
Taylor A ImburgiaSamantha R EngdahlRebecca S PettitPublished in: Pediatric pulmonology (2022)
No difference in risk of ADEs including AKI was seen with cefepime PI in pediatric CF patients. Clinical outcomes were not significantly different between groups, but sample size may have limited comparison. PI cefepime may be considered in pediatric CF patients to optimize pharmacodynamics.